» Articles » PMID: 29914056

Real-Time Imaging of Retinal Ganglion Cell Apoptosis

Overview
Journal Cells
Publisher MDPI
Date 2018 Jun 20
PMID 29914056
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Monitoring real-time apoptosis in-vivo is an unmet need of neurodegeneration science, both in clinical and research settings. For patients, earlier diagnosis before the onset of symptoms provides a window of time in which to instigate treatment. For researchers, being able to objectively monitor the rates of underlying degenerative processes at a cellular level provides a biomarker with which to test novel therapeutics. The DARC (Detection of Apoptosing Retinal Cells) project has developed a minimally invasive method using fluorescent annexin A5 to detect rates of apoptosis in retinal ganglion cells, the key pathological process in glaucoma. Numerous animal studies have used DARC to show efficacy of novel, pressure-independent treatment strategies in models of glaucoma and other conditions where retinal apoptosis is reported, including Alzheimer’s disease. This may forge exciting new links in the clinical science of treating both cognitive and visual decline. Human trials are now underway, successfully demonstrating the safety and efficacy of the technique to differentiate patients with progressive neurodegeneration from healthy individuals. We review the current perspectives on retinal ganglion cell apoptosis, the way in which this can be imaged, and the exciting advantages that these future methods hold in store.

Citing Articles

Retinal Ganglion Cell Replacement in Glaucoma Therapy: A Narrative Review.

Kosior-Jarecka E, Grzybowski A J Clin Med. 2024; 13(23).

PMID: 39685661 PMC: 11642712. DOI: 10.3390/jcm13237204.


Magnesium and Its Role in Primary Open Angle Glaucoma; A Novel Therapeutic?.

Elghobashy M, Lamont H, Morelli-Batters A, Masood I, Hill L Front Ophthalmol (Lausanne). 2024; 2:897128.

PMID: 38983515 PMC: 11182183. DOI: 10.3389/fopht.2022.897128.


Alzheimer's disease pathophysiology in the Retina.

Gaire B, Koronyo Y, Fuchs D, Shi H, Rentsendorj A, Danziger R Prog Retin Eye Res. 2024; 101:101273.

PMID: 38759947 PMC: 11285518. DOI: 10.1016/j.preteyeres.2024.101273.


Application of Proteomics Analysis and Animal Models in Optic Nerve Injury Diseases.

Meng Z, You R, Mahmood A, Yan F, Wang Y Brain Sci. 2023; 13(3).

PMID: 36979214 PMC: 10046207. DOI: 10.3390/brainsci13030404.


Solving neurodegeneration: common mechanisms and strategies for new treatments.

Wareham L, Liddelow S, Temple S, Benowitz L, Di Polo A, Wellington C Mol Neurodegener. 2022; 17(1):23.

PMID: 35313950 PMC: 8935795. DOI: 10.1186/s13024-022-00524-0.


References
1.
Morrison J, Moore C, Deppmeier L, Gold B, Meshul C, Johnson E . A rat model of chronic pressure-induced optic nerve damage. Exp Eye Res. 1997; 64(1):85-96. DOI: 10.1006/exer.1996.0184. View

2.
Cheung W, Guo L, Cordeiro M . Neuroprotection in glaucoma: drug-based approaches. Optom Vis Sci. 2008; 85(6):406-16. PMC: 2597725. DOI: 10.1097/OPX.0b013e31817841e5. View

3.
Park J, Jang J, Choi E, Kim Y, Lee E, Jung I . Annexin A5 increases survival in murine sepsis model by inhibiting HMGB1-mediated pro-inflammation and coagulation. Mol Med. 2016; 22:424-436. PMC: 5072405. DOI: 10.2119/molmed.2016.00026. View

4.
Davis B, Tian K, Pahlitzsch M, Brenton J, Ravindran N, Butt G . Topical Coenzyme Q10 demonstrates mitochondrial-mediated neuroprotection in a rodent model of ocular hypertension. Mitochondrion. 2017; 36:114-123. PMC: 5645575. DOI: 10.1016/j.mito.2017.05.010. View

5.
Creutz C, Hira J, Gee V, Eaton J . Protection of the membrane permeability barrier by annexins. Biochemistry. 2012; 51(50):9966-83. DOI: 10.1021/bi3013559. View